Marcellus Cephas, MD
Psychiatry · Whitesboro, NYNPI 1134116007
Payments from drug & device makers
Across 183 payments — averaging $56.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Johnson & Johnson$559
- Teva Pharmaceuticals USA, Inc.$474
- Vanda Pharmaceuticals Inc.$413
- Otsuka America Pharmaceutical, Inc.$252
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$248
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$7,00068%
- Food & beverage$3,20931%
- Education$1461%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 21 | $7,250 |
| Johnson & Johnson | 25 | $559 |
| Teva Pharmaceuticals USA, Inc. | 27 | $474 |
| Vanda Pharmaceuticals Inc. | 20 | $413 |
| Otsuka America Pharmaceutical, Inc. | 15 | $252 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $248 |
| Alkermes, Inc. | 10 | $171 |
| Lundbeck LLC | 7 | $146 |
| Neurocrine Biosciences, Inc. | 7 | $120 |
| Indivior Inc. | 5 | $109 |
| Ironshore Pharmaceuticals Inc. | 6 | $103 |
| Axsome Therapeutics, Inc. | 4 | $93 |
| Jazz Pharmaceuticals Inc. | 4 | $76 |
| Corium, LLC | 3 | $62 |
| Eisai Inc. | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Braeburn Inc. | 2 | $36 |
| Almatica Pharma LLC | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Shire North American Group Inc | 2 | $30 |
| Bausch Health US, LLC | 1 | $23 |
| Tris Pharma Inc | 1 | $21 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$7,117
How this compares
$10,355 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 14 | $44,641 |
| Clozapine | 30 | $1,971 |
| Quetiapine Fumarate | 34 | $1,472 |
| Aripiprazole | 28 | $1,338 |
| Haloperidol | 21 | $939 |
| Paliperidone ErPaliperidone | 12 | $830 |
| Ziprasidone Hcl | 26 | $756 |
| Oxcarbazepine | 11 | $706 |
| Divalproex Sodium | 19 | $599 |
| Olanzapine | 20 | $319 |
| Benztropine Mesylate | 22 | $246 |
| Propranolol Hcl | 16 | $183 |
| Trazodone Hcl | 20 | $178 |
| Lithium Carbonate | 11 | $172 |
| Risperidone | 11 | $162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $559 | $44,64114 claims |
| Almatica Pharma LLCSertraline Hcl | $35 | $15911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Whitesboro
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
- Paul EderNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.